CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Breast Ductal Lavage for Detection of Breast Cancer

Defines coverage stance for breast ductal lavage (ductal lavage) and fiberoptic ductoscopy for detection, diagnosis, or treatment of breast cancer for Medicare Advantage and Commercial products offered by Blue Cross Blue Shield Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Breast Ductal Lavage for Detection of Breast Cancer

Policy CodePolicy N/A

Change TypeNo material change

Effective DateSep 1, 2001

Next Review Date

Key ActionFile claims for breast ductal lavage or fiberoptic ductoscopy with CPT code 19499 (Unlisted procedure, breast) and expect these services may be denied as not covered or not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material changes to clinical coverage or policy determinations (has_material_change=false).

2Procedures classified as not covered / not medically necessary

1Unlisted CPT code recommended for claims

Coverage Summary

Overview: This policy addresses Breast ductal lavage and Fiberoptic ductoscopy for detection, diagnosis, or treatment of breast cancer. Scope: defines coverage stance for these procedures for Medicare Advantage and Commercial products offered by Blue Cross Blue Shield Rhode Island. Coverage stance: Not covered / Not medically necessary (cosmetic). Effective date: 2001-09-01. Last review: 2024-02-21.

Medical Necessity / Coverage Determinations

Medicare Advantage Plans - Coverage Determination

Breast ductal lavage and fiberoptic ductoscopy are considered not covered when the following rationale applies:

ALL of the following

Ductal lavage not covered: Evidence is insufficient to determine the effects of the technology on health outcomes in comparison to more established techniques for acquisition and evaluation of breast cytology
Applies to breast ductal lavage
Fiberoptic ductoscopy not covered: Evidence is insufficient to determine the effects of breast duct endoscopy (fiberoptic ductoscopy) on health outcomes or to permit scientific conclusion regarding its role in evaluation and management of patients with known or suspected breast cancer
Applies to fiberoptic ductoscopy

Commercial Products - Medical Necessity Determination

Breast ductal lavage and fiberoptic ductoscopy are considered not medically necessary when the following rationale applies:

ALL of the following

Ductal lavage not medically necessary: Evidence is insufficient to determine the effects of the technology on health outcomes in comparison to more established techniques for acquisition and evaluation of breast cytology
Applies to breast ductal lavage
Fiberoptic ductoscopy not medically necessary: Evidence is insufficient to determine the effects of breast duct endoscopy (fiberoptic ductoscopy) on health outcomes or to permit scientific conclusion regarding its role in evaluation and management of patients with known or suspected breast cancer
Applies to fiberoptic ductoscopy

ref

Not Covered / Experimental Rationale

Background and evidence sufficiency: Ductal lavage collects breast ductal epithelial cells via microcatheter and saline flush for cytological analysis and has been proposed as a risk assessment tool in high-risk women; fiberoptic ductoscopy provides direct visual examination of breast ducts. The evidence is limited: there is no consensus among cytopathologists on interpretation of ductal lavage specimens, limited data on how results affect patient management, and minimal published information on clinical use of ductoscopy. Therefore the evidence is insufficient to determine effects on health outcomes compared with established techniques (eg, mammography, nipple aspiration) and to support coverage or medical necessity.

Ductal lavage: Method of collecting breast ductal epithelial cells by inserting a microcatheter into milk ducts and flushing with saline for cytological examination.

Fiberoptic ductoscopy: Direct visual examination of breast ducts through nipple orifice cannulation using a fiberoptic endoscope.

Provider Actions

Billing Rule

Use unlisted CPT for claims

Claims for breast ductal lavage or fiberoptic ductoscopy should be filed with CPT code 19499 (Unlisted procedure, breast) because there is no specific CPT code for these services.

19499

Denial Risk

Not covered / Not medically necessary services

Breast ductal lavage and fiberoptic ductoscopy are considered not covered for Medicare Advantage and not medically necessary for commercial products; claims may be denied on that basis.

Medicare Advantage
Commercial
Claims may be denied as not covered / not medically necessary

Background and Evidence

Context and comparison: Ductal lavage is intended to retrieve ductal epithelial cells from individual milk ducts (each breast has ~6–8 ducts) to improve cell yield over nipple aspiration and to serve as a nonsurgical risk assessment tool for high-risk patients. Mammography remains the standard for early detection; by contrast, ductal lavage techniques lack reproducible interpretation criteria and sufficient controlled studies to determine effectiveness, accuracy, safety, or how results modify management. Fiberoptic ductoscopy has been explored for follow-up of atypical cytology, evaluation of spontaneous nipple discharge, delineation of ductal disease for surgical planning, and local therapy delivery, but there is minimal evidence on its influence on diagnostic or treatment decisions.

Evidence sufficiency: Insufficient — the available data are limited, lack consensus on cytologic interpretation, and do not demonstrate that ductal lavage or fiberoptic ductoscopy improve health outcomes or meaningfully change clinical management compared with established diagnostic methods.

Ductal lavage: Method of collecting breast ductal epithelial cells by inserting a microcatheter into milk ducts and flushing with saline for cytological examination.

Fiberoptic ductoscopy: Direct visual examination of breast ducts through nipple orifice cannulation using a fiberoptic endoscope.

Revision History

2001-09-01effective_date

Policy effective date: coverage policy for breast ductal lavage and fiberoptic ductoscopy established; ductal lavage described as method for collecting ductal epithelial cells for cytologic analysis and potential risk assessment in high-risk women.

2024-02-21last_reviewLatest

Policy last reviewed: reaffirmed that breast ductal lavage and fiberoptic ductoscopy are considered not covered/not medically necessary due to insufficient evidence that these technologies improve health outcomes or inform management compared with established techniques; recommended billing with CPT 19499 (Unlisted procedure, breast) because no specific CPT exists.